...imaging and myocardial perfusion imaging (MPI) studies. Adenosine Therapeutics LLC markets the ADORA2A agonist Stedivaze apadenoson...

...ADORA2A agonist Lexiscan regadenoson as a cardiovascular imaging agent. Adenosine Therapeutics LLC's ADORA2A agonist Stedivaze apadenoson...

...ADORA2A agonist Lexiscan regadenoson as a cardiovascular imaging agent. Adenosine Therapeutics LLC's ADORA2A agonist Stedivaze apadenoson...

...ADORA2A agonists in animal models of NPC1. Adenosine Therapeutics LLC has the ADORA2A agonist Stedivaze apadenoson...

...ADORA2A agonist Lexiscan regadenoson as a cardiovascular imaging agent. Adenosine Therapeutics LLC's ADORA2A agonist, Stedivaze apadenoson...

...Needham to explore strategic alternatives for Stedivaze apadenoson, which could include regional or global partners. Stedivaze...
...myocardial perfusion imaging (MPI). Clinical Data acquired substantially all of Adenosine's assets in 2008, including Stedivaze...
...Adenosine declined to disclose details, including the terms under which the company re-acquired rights to Stedivaze...

...Inc. ; Pfizer Inc. 's binodenoson, which is in registration; and Forest Laboratories Inc. 's apadenoson...

...Inc. ; Pfizer Inc. 's binodenoson, which is in registration; and Forest Laboratories Inc. 's apadenoson...

...binodenoson in registration for cardiovascular imaging. Forest Laboratories Inc. has the ADORA 2A agonist Stedivaze apadenoson...

...of either the product or the company. Clinical Data has two other clinical programs: Stedivaze apadenoson...